Skip to main content

Single Ventricle Heart Disease

3
Pipeline Programs
2
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Mezzion Pharmaceuticals
3 programs
3
UdenafilPhase 31 trial
UdenafilPhase 31 trial
UdenafilPhase 31 trial
Active Trials
NCT02741115Completed400Est. Apr 2019
NCT05918211Recruiting436Est. Oct 2025
NCT03430583Completed88Est. Sep 2020
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Cognitive Computer Based InterventionN/A1 trial
Active Trials
NCT03687008Completed5Est. Jun 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Mezzion PharmaceuticalsUdenafil
Mezzion PharmaceuticalsUdenafil
Mezzion PharmaceuticalsUdenafil
Angeles TherapeuticsCognitive Computer Based Intervention

Clinical Trials (4)

Total enrollment: 929 patients across 4 trials

Fontan Udenafil Exercise Longitudinal Assessment Trial - 2

Start: Oct 2023Est. completion: Oct 2025436 patients
Phase 3Recruiting

Evaluation of Fontan-associated Hepatic Stiffness and the Efficacy of Udenafil in Reducing Liver Stiffness

Start: Feb 2018Est. completion: Sep 202088 patients
Phase 3Completed

Fontan Udenafil Exercise Longitudinal Assessment Trial

Start: Jul 2016Est. completion: Apr 2019400 patients
Phase 3Completed
NCT03687008Angeles TherapeuticsCognitive Computer Based Intervention

Cognitive Intervention to Improve Working Memory

Start: Jun 2021Est. completion: Jun 20225 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 929 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.